Journal article
Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial
Abstract
BACKGROUND: Asundexian (Bayer AG, Leverkusen, Germany), an oral small molecule factor XIa (FXIa) inhibitor, might prevent thrombosis without increasing bleeding. Asundexian's effect for secondary prevention of recurrent stroke is unknown.
METHODS: In this randomised, double-blind, placebo-controlled, phase 2b dose-finding trial (PACIFIC-Stroke), patients with acute (within 48 h) non-cardioembolic ischaemic stroke were recruited from 196 …
Authors
Shoamanesh A; Mundl H; Smith EE; Masjuan J; Milanov I; Hirano T; Agafina A; Campbell B; Caso V; Mas J-L
Journal
The Lancet, Vol. 400, No. 10357, pp. 997–1007
Publisher
Elsevier
Publication Date
September 2022
DOI
10.1016/s0140-6736(22)01588-4
ISSN
0140-6736